Why certain cancer therapeutics may bind—or fail to bind—to mutant proteins

January 16, 2018, Agency for Science, Technology and Research (A*STAR), Singapore
Why certain cancer therapeutics may bind — or fail to bind — to mutant proteins
Molecular simulation of afatinib (magenta) bound to EGFR19del (gray), with a single water molecule (red sphere) mediating interactions (dotted line) between the drug and the protein. Other mutation-prone amino acids within the drug-binding pocket are individually colored. Credit: A*STAR Bioinformatics Institute

A single molecule of water is the reason certain mutations are more responsive to a 'targeted' cancer therapy, according to molecular-scale simulations carried out at the A*STAR Bioinformatics Institute.

Targeted therapies that take down tumors by selectively interfering with the defective proteins that promote their survival and growth have revolutionized . For example, the drug afatanib is a targeted agent given to with certain mutations in the gene encoding the epidermal growth factor receptor (EGFR). Recent clinical studies suggest that afatanib may confer survival benefit specifically in patients with the EGFR19del mutation rather than in patients with a different mutation, known as EGFRL858R, when compared with receiving only standard chemotherapy.

Daniel Shao-Weng Tan, a clinical oncologist from A*STAR's Genome Institute of Singapore and the National Cancer Center of Singapore, who participated in these trials in Singapore, was confounded by this disparity, so he consulted scientist Chandra Verma at the Bioinformatics Institute to rationalize their findings. Verma and Srinivasaraghavan Kannan, a specialist in molecular modeling at the Bioinformatics Institute, teamed up with Tan to identify differences in the structure and dynamic behavior of these two mutant proteins that might explain the distinct response profiles.

It turns out that the critical difference was a mere molecule of water. Afatanib binds to a pocket on EGFR that is missing five amino acids in the EGFR19del mutant. Molecular dynamics simulations carried out at the Bioinformatics Institute and the National Supercomputing Centre, Singapore, showed that this deletion creates a more physically constrained structure, which can snugly accommodate both afatanib and a single water molecule in a very stable arrangement. In contrast, the mutant EGFRL858R, also found to characterize lung , contains just a single amino acid substitution, and is predicted to hold two water molecules in its pocket. However, these are in a weaker and relatively less stable arrangement, resulting in weakened interactions with afatanib that likely reduce the drug's affinity and hence effectiveness.

"Our hypothesis is based on understanding the physics of the system and could offer a compelling rationale for the clinical observations with afatanib," says Kannan. Intriguingly, he and Verma were also able to home in on other binding pocket mutations (single nucleotide polymorphisms, or 'SNPs') that occur alongside EGFR19del that might likewise influence the efficacy of afatanib.

The researchers are now examining whether these predictions hold in real-life experiments and see this as a promising general strategy for predicting patient response to targeted treatments. "We are trying to develop a robust pipeline to examine the structural effects of on drug interactions," Kannan says. "This will be a very valuable approach to complement our engagement with the national precision medicine efforts."

Explore further: Investigators match novel cancer mutations with potential therapies

More information: Srinivasaraghavan Kannan et al. Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib, Scientific Reports (2017). DOI: 10.1038/s41598-017-01491-z

Related Stories

Investigators match novel cancer mutations with potential therapies

August 4, 2017
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

September 11, 2017
Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented ...

Not all EGFR mutations are the same when it comes to therapy for non-small cell lung cancer

February 10, 2015
Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common "classical" ...

Cancer drug design targeted by COSMIC's new 3-D system

May 10, 2017
COSMIC-3D, the most comprehensive system for exploring cancer mutations in three dimensions, is launched today by COSMIC, based at the Wellcome Trust Sanger Institute, in collaboration with Astex Pharmaceuticals, Cambridge, ...

targeted therapy can delay recurrence of intermediate-stage lung cancer

May 18, 2017
The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor ...

Recommended for you

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.